{"id":2759,"date":"2021-02-18T16:17:11","date_gmt":"2021-02-18T05:17:11","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/cbd-products-under-serious-review-in-e-u\/"},"modified":"2021-02-18T16:17:11","modified_gmt":"2021-02-18T05:17:11","slug":"cbd-products-under-serious-review-in-e-u","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/cbd-products-under-serious-review-in-e-u\/","title":{"rendered":"CBD Products Under Serious Review in E.U."},"content":{"rendered":"<p><strong>EU drug agency flags CBD market issues in report on low-THC cannabis products<\/strong><\/p>\n<p>The European Union\u2019s drug agency has signaled that it is mulling the legal and commercial status of CBD and cannabis-based products in Europe in a new report.<\/p>\n<p>The Lisbon-based European Monitoring Centre for Drugs and Drug Addiction published the report on Monday, detailing the results of a study that kicked off in 2018 and aimed to provide insight into the open sale of low-THC products in Europe.<\/p>\n<p>\u201cThe specific objectives were to identify and further explore the types of product available and the range of sales outlets, user profiles, associated harms and responses taken in different EU countries,\u201d the authors wrote.<\/p>\n<p>The Centre took note of several glaring issues with the marketing and promotion of some CBD products across Europe, including:<\/p>\n<p><a href=\"https:\/\/hempindustrydaily.com\/eu-drug-agency-flags-cbd-market-issues-in-report-on-low-thc-cannabis-products\/\"><\/a>for more&nbsp;<a href=\"https:\/\/hempindustrydaily.com\/eu-drug-agency-flags-cbd-market-issues-in-report-on-low-thc-cannabis-products\/\">https:\/\/hempindustrydaily.com\/eu-drug-agency-flags-cbd-market-issues-in-report-on-low-thc-cannabis-products\/<\/a><\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-2758\" src=\"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-scaled.jpg\" alt=\"Handbook CannabisPathologies\" width=\"530\" height=\"701\" style=\"display: block; margin-left: auto; margin-right: auto;\" srcset=\"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-scaled.jpg 1936w, https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-227x300.jpg 227w, https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-774x1024.jpg 774w, https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-768x1016.jpg 768w, https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-1162x1536.jpg 1162w, https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-content\/uploads\/2021\/02\/Handbook_CannabisPathologies-1549x2048.jpg 1549w\" sizes=\"(max-width: 530px) 100vw, 530px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EU drug agency flags CBD market issues in report on low-THC cannabis products The European Union\u2019s drug agency has signaled that it is mulling the legal and commercial status of CBD and cannabis-based products in Europe in a new report. The Lisbon-based European Monitoring Centre for Drugs and Drug Addiction published the report on Monday, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2758,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":"","_wp_rev_ctl_limit":""},"categories":[46],"tags":[],"class_list":["post-2759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-next-phase-platform"],"_links":{"self":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/2759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/comments?post=2759"}],"version-history":[{"count":0,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/2759\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/media\/2758"}],"wp:attachment":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/media?parent=2759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/categories?post=2759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/tags?post=2759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}